Gene therapy for neurological disease

Expert Opinion on Biological Therapy

Volumn 3, Issue 5, 2003, Pages 815-828

  Tuszynski, Mark H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Alzheimer's disease; Brain derived neurotrophic factor; Canavan's disease; Clinical trials; Gene therapy; Glial line derived neurotrophic factor; Growth factors; Inborn errors of metabolism; Nerve growth factor; Neurodegeneration; Neurological disease

Indexed keywords

ADENOVIRUS VECTOR; ASPARTOACYLASE; BETA N ACETYLHEXOSAMINIDASE; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; HERPESVIRUS VECTOR; NERVE GROWTH FACTOR; NEURITE PROMOTING FACTOR; NEUROTROPHIN 3; NEURTURIN; PARVOVIRUS VECTOR; RETROVIRUS VECTOR; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ALZHEIMER DISEASE; CANAVAN DISEASE; CELL DEATH; CELL SURVIVAL; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE TARGETING; GENE THERAPY; HUMAN; LHERMITTE DUCLOS DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; REVIEW; SCHWANN CELL; SIDE EFFECT; SPINAL CORD INJURY; TAY SACHS DISEASE; VIRAL GENE DELIVERY SYSTEM; VOMITING; WEIGHT REDUCTION;

ALZHEIMER DISEASE; ANIMALS; CELL TRANSPLANTATION; GENE THERAPY; HUMANS; METABOLISM, INBORN ERRORS; NERVE GROWTH FACTOR; NERVOUS SYSTEM DISEASES; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; SPINAL CORD INJURIES;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; HERPESVIRIDAE; PARVOVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0041701529     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.5.815     Document Type: Review

References (110)

1. BLESCH A, GRILL RJ, TUSZYNSKI MH: Neurotrophin gene therapy in models of CNS trauma and neurodegeneration. Prog. Brain Res. (1998) 117:473-484.
2. BRUSTLE O, MCKAY RD: Neuronal progenitors as tools for cell replacement in the nervous system. Curr. Opin. Neurobiol. (1996) 6:688-695. An excellent review of the therapeutic potential of stem-like cells for neurotherapy.
3. MUZYCZKA N: Use of anedo-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. (1992) 158:97-129.
4. NALDINI L, BLOMER U, GALLAY P et al.: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 272:263-267.
5. RABINOWITZ JE, SAMULSKI RJ: Building a better vector: the manipulation of AAV virions. Virology (2000) 278:301-308.
6. JACOBS A, BREAKEFIELD XO, FRAEFEL C: HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis. Neoplasia (1999) 1:387-401.
7. MILLER DA: Retrovirus packaging cells. Hum. Gene Ther. (1990) 1:5-14.
8. RABINOWITZ JE, SAMULSKI J: Adeno-associated virus expression systems for gene transfer. Curr. Opin. Biotechnol. (1998) 9:470-475. Excellent summary of AAV expression systems for gene therapy.
9. GLORIOSO JC, DELUCA NA, FINK DJ: Development and application of herpes simplex virus vectors for human gene therapy. Ann. Rev. Microbiol. (1995) 49:675-710.
10. HEISTER T, HEID I, ACKERMANN M, FRAEFEL C: Herpes simplex virus Type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19. J. Virol. (2002) 76:7163-7173.
11. WANG Y, CAMP SM, NIWANO M et al.: Herpes simplex virus Type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration. J. Virol. (2002) 76:7150-7162.
12. MAGUIR-ZEIS KA, BOWERS WJ, FEDEROFF HJ: HSV vector-mediated gene delivery to the central nervous system. Curr. Opin. Mol. Ther. (2001) 3:482-490.
13. YANT SR, EHRHARDT A, MIKKELSEN JG, MEUSE L, PHAM T, KAY MA: Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat. Biotechnol. (2002) 20:999-1005.
14. MCKAY R: Reconstituting animals from immortal precursors. Curr. Opin. Neurobiol. (1992) 2:582-585.
15. WHITTEMORE SR, EATON MJ, ONIFER SM: Gene therapy and the use of stem cells for central nervous system regeneration. Adv. Neurol. (1997) 72:113-119.
16. TUSZYNSKI MH: Gene therapy for neurodegenerative disorders. Lancet Neurol. (2002) 2002:51-57.
17. LEVI-MONTALCINI R, HAMBURGER V: Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J. Exp. Zool. (1951) 116:321-362. A landmark description of the discovery of growth factors.
18. LEVI-MONTALCINI R: The nerve growth factor 35 years later. Science (1987) 237:1154-1162. A summary of knowledge regarding NGF actions, as a paper accompanying the award of the Nobel Prize for the discovery of NGF.
19. ANGELETTI RH, HERMODSON MA, BRADSHAW RA: Amino acid sequences of mouse 2.5S nerve growth factor. II. Isolation and characterization of the thermolytic and peptic peptides and the complete covalent structure. Biochemistry (Mosc.) (1973) 12:100-115.
20. ULLRICH A, GRAY A, BERMAN C, DULL TJ: Human bera-nerve growth factor gene sequence highly homologous to that of mouse. Nature (1983) 303:821-825.
21. HEFTI F: Nerve growth factor (NGF) promotes survival of septal cholinergic neurons after fimbrial transection. J. Neurosci. (1986) 6:2155-2162. The first report that any growth factor prevents cell death in the adult nervous system.
22. WILLIAMS LR, VARON S, PETERSON GM et al.: Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria-fornix transection. Proc. Natl. Acad. Sci. USA (1986) 83:9231-9235.
23. KROMER LF: Nerve growth factor treatment after brain injury prevents neuronal death. Science (1987) 235:214-216.
24. FISCHER W, WICTORIN K, BJORKLUND A, WILLIAMS LR, VARON S, GAGE FH: Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature (1987) 329:65-68. A landmark study that NGF reverses age-related nearonal atrophy and improves memory.
25. TUSZYNSKI MH, U H-S, AMARAL DG, GAGE FH: Nerve growth factor infusion in primate brain reduces lesion-induced cholinergic neuronal degeneration. J. Neurosci. (1990) 10:3604-3614. The first report that growth factors prevent cell degeneration in the primate brain.
26. KOLIATSOS VE, NAUTA HJ, CLATTERBUCK RE, HOLTZMAN DM, MOBLEY WC, PRICE DL: Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in the monkey. J. Neurosci. (1990) 10:3801-3813.
27. TUSZYNSKI MH, U H-S, GAGE FH: Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann. Neurol. (1991) 30:625-636.
28. HEFTI F, WEINER WJ: Nerve growth factor and Alzheimer's disease. Ann. Neurol. (1986) 20:275-281.
29. PHELPS CH, GAGE FH, GROWDON H et al.: Potential use of nerve growth factor to treat Alzheimer's disease. Neurobiol. Aging (1989) 10:205-207.
30. PERRY EY, PERRY RH, BLESSED G, TOMLINSON BE: Necropsy evidence of central cholinergic deficits in senile dementia. Lancet (1977) 2:143. The first report that cholinergic neurons degenerate extensively in AD.
31. WHITEHOUSE PJ, PRICE DJ, CLARK A, COYLE JT, DELONG M: Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. (1981) 10:122-126.
32. PERRY EK, TOMLINSON BE, BLESSED G, BERGMANN K, GIBSON PH, PERRY RH: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. (1978) 2:1457-1459. An important report that loss of cholinergic function parallels cognitive and pathological decline in AD.
33. WHITEHOUSE PJ, PRICE DL, STRUBLE RG, CLAR AW, COYLE JT, DELONG MR: Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science (1982) 215:1237-1239. This report together with the publication below, highlighted the importance of cholinergic system loss in AD.
34. BARTUS R, DEAN RL, BEER C, LIPPA AS: The cholinergic hypothesis of geriatric memory dysfunction. Science (1982) 217:408-417. See [33].
35. CANDY JM, PERRY RH, PERRY EK et al.: Pathological changes in the nucleus basalis of Meynert in Alzheimer's and Parkinson's diseases. J. Neurosci. (1983) 54:277-289.
36. MUFSON EJ, CONNER JM, KORDOWER JH: Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. Neuroreport (1995) 6:1063-1066. Important finding that NGF is deficient in the AD-affected brain.
37. SCOTT SA, MUFSON EJ, WEINGARTNER JA, SKAU KA, CRUTCHER KA: Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J. Neurosci. (1995) 15:6213-6221.
38. EMMETT CJ, STEWART GR, JOHNSON RM, ASWANI SP, CHAN RL, JAKEMAN LB: Distribution of radioiodinated recombinant human nerve growth factor in primate brain following intracerbroventficular infusion. Exp. Neurol. (1996) 140:151-160.
39. ISAACSON LG, SAFFRAN BN, CRUTCHER KA: Intracerebral NGF infusion induces hyperinnervation of cerebral blood vessels. Neurobiol. Aging (1990) 11:51-55.
40. WILLIAMS LR: Hypophagia is induced by intracerebroventricular administration of nerve growth factor. Exp. Neurol. (1991) 113:31-37.
41. WINKLER J, RAMIREZ GA, KUHN HG et al.: Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Ann. Neurol. (1997) 41:82-93.
42. EMMETT CJ, STEWART GR, JOHNSON RM, ASWANI SP, CHAN RL, JAKEMAN LB: Distribution of radioiodinated recombinant human nerve growth factor in primate brain following intracerebroventricular infusion. Exp. Neurol. (1996) 140:151-160.
43. ERIKSDOTTER JONHAGEN M, NORDBERG A, AMBERLA K et al.: Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord (1998) 9:246-257. First clinical trial of NGF in AD, using flawed intraventricular infusions.
44. ROSENBERG MB, FRIEDMANN T, ROBERTSON RC et al.: Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science (1988) 242:1575-1578. First successful use of gene therapy in the brain.
45. CHEN KS, GAGE FH: Somatic gene transfer of NGF to the aged brain: behavioral and morphological amelioration. J. Neurosci. (1995) 15:2819-2825.
46. TUSZYNSKI MH, ROBERTS J, SENUT MC, U H-S, GAGE FH: Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther. (1996) 3:305-314.
47. EMERICH DW, WINN S, HARPER J, HAMMANG JP, BAETGE EE, KORDOWER JH: Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons. J. Comp. Neurol. (1994) 349:148-164. First report of success of NGF gene delivery in the primate brain.
48. KORDOWER JH, WINN SR, LIU Y-T et al.: The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc. Natl. Acad. Sci. (1994) 91:10898-10902.
49. SMITH DE, ROBERTS J, GAGE FH, TUSZYNSKI MH: Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc. Nat. Acad. Sci. (1999) 96:10893-10898. First report that NGF gene therapy reverses spontaneous age-related cholinergic atrophy primates.
50. DEKKER AJ, LANGDON DJ, GAGE FH, THAL LJ: NGF increases cortical acetylcholine release in rats with lesions of the nucleus basalis. Neuroreport (1991) 2:577-580.
51. MUFSON EJ, CONNER JM, KORDOWER JH: Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. Neuroreport (1995) 6:1063-1066.
52. MANDEL RJ, GAGE FH, CLEVENGER SK, SNYDER RO, LEFF SE: Nerve growth factor expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration. Exp. Neurol. (1999) 155:59-64.
53. KLEIN RL, HIRKO AC, MEYERS CA, GRIMES JR, MUZYCZKA N, MEYER EM: NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res. (2000) 875:144-151.
54. TUSZYNSKI MH: Neurotrophic factors. In: CNS Regeneration: Basic Science and Clinical Advances, Tuszynski MH, Kordower JA (Eds), Academic Press, San Diego, USA (1999):109-158.
55. PHILLIPS HS, HAINS JM, ARAMANI M, LARAMEE GR, JOHNSON SA, WINSLOW JW: BDNF is decreased in the hipocampus of individuals with Alzheimer's disease. Neuron (1991) 7:695-702.
56. GOMEZ-PEIULLA F, LEE JW, COTMAN CW: Basic fibroblast growth factor in adult rat brain: cell distribution and response to entorhinal lesion and fimbria-fornix transection. J. Neurosci. (1992) 12:345-355.
57. PETERSON DA, LUCIDI-PHILLIPI CA, MURPHY DP, RAY J, GAGE FH: Fibroblast growth factor-2 protects entorhinal layer II glutamatergic neurons from axotomy-induced death. J. Neurosci. (1996) 16:886-898.
58. SPINA MB, HYMAN C, SQUINTO S, LINDSAY RM: Brain-derived neurotrophic factor protects dopaminergic cells from 6-hydroxydopamine toxicity. Ann. NY Acad. Sci. (1992) 648:348-350.
59. LIN LF, DOHERTY DH, LILE JD, BEKTESH S, COLLINS F: GDNF: a glial cell-line derived neurotrophic factor for midbrain dopaminergic neurons. Science (1993) 260:1130-1132.
60. FRIM DM, UHLER TA, SHORT MP et al.: Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. Neuroreport (1993) 4:367-370.
61. HYMAN C, HOFER M, JUHASZ M, YANCOPOULOS GP, SQUINTO SP, LINDSAY RM: Brain derived neurotrophic factor is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature (1994) 350:230-232.
62. WINKLER C, SAUER H, LEE CS, BJORKLUND A: Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. (1996) 16:7206-7215.
63. KOTZBAUER PT, LAMPE PA, HEUCKEROTH RO et al.: Neurturin, a relative of glial-cell-line derived neurotrophic factor. Nature (1996) 384:467-470.
64. BJORKLUND A, KIRIK D, ROSENBLAD C, GEORGIEVSKA B, LUNDBERG C, MANDEL RJ: Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. (2000) 886:82-98.
65. CONNOR B, KOZLOWSKI DA, SCHALLERT T, TILLERSON JL, DAVIDSON BL, BOHN MC: Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther. (1999) 6:1936-1951.
66. GASH DM, ZHANG Z, OVADIA A et al.: Functional recovery in parkinsonian monkeys treated with GDNF. Nature (1996) 380:252-255. Important finding that GDNF improves symptoms and protects nigral neurons in a primate model of PD.
67. KORDOWER JH, EMBORG ME, BLOCH J et al.: Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science (2000) 290:767-773. Landmark study demonstrating that GDNF in vivo gene delivery supports nigral neurons in MPTP-lesioned and aged primates, and promotes functional recovery in MPTP-lesioned monkeys.
68. NUTT JG, BURCHIEL KJ, COMELLA CL et al.: Randomized, double-blind trial of glial cell line-derived neurotorphic factor (GDNF) in PD. Neurology (2003) 60:69-73.
69. KIRIK D, ROSENBLAD C, BJORKLUND A, MANDEL R: Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transudction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. (2000) 20:4686-4700.
70. MUFSON EJ, KROIN JS, LIU YT et al.: Intrastriatal and intraventricular infusion of brain-derived neurotrophic factor in the cynomologous monkey: distribution, retrograde transport and co-localization with substantia nigra dopamine-containing neurons. Neuroscience (1996) 71:179-191.
71. WOLFF JA, FISHER LJ, XU L et al.: Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA (1989) 86:9011-9014.
72. KANG UJ, FISHER LJ, JOH TH, O'MALLEY KL, GAGE FH: Regulation of dopamine production by genetically modified primary fibroblasts. J. Neurosci. (1993) 13:5203-5211.
73. AZZOUZ M, MARTIN-RENDON E, BARBER RD et al.: Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cydohydrolase I induced sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J. Neurosci. (2002) 22:10302-10312.
74. BANKIEWICZ KS, BRINGAS JR, MCLAUGHLIN W et al.: Application of gene therapy for Parkinson's disease: nonhuman primate experience. Adv. Pharmacol. (1998) 42:801-806.
75. LUO J, KAPLITT MG, FITZSIMONS HL et al.: Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science (2002) 298:425-429.
76. EMERICH DF, LINDNER MD, WINN SR, CHEN EY, FRYDEL BR, KORDOWER JH: Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J. Neurosci. (1996) 16:5168-5181.
77. EMERICH DF, WINN SR, HANTRAYE PM et al.: Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature (1997) 386:395-399. Important report that the growth factor CNTF reverses neuronal degeneration in a primate model of Huntington's disease.
78. NO AUTHORS LISTED: A double-blind placebo-controlled trial of subcutaneous recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. A-CT GROUP S. Neurology (1996) 46:1244-1249.
79. NO AUTHORS LISTED: A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF Study Group (Phase III). TB GROUP S. Neurology (1999) 52:1427-1433.
80. GRILL R, MURAI K, BLESCH A, GAGE FH, TUSZYNSKI MH: Cellular delivery of neurotrophin-3 promotes corticospinal axonal growth and partial functional recovery after spinal cord injury. J. Neurosci. (1997) 17:5560-5572.
81. LIU Y, KIM D, HIMES BT et al.: Transplants of fibroblasts genetically modified to express BDNF promote regeneration of adult rat rubrospinal axons and recovery of forelimb function. J. Neurosci. (1999) 19:4370-4387.
82. TUSZYNSKI MH, GRILL R, JONES L, MCKAY HM, BELSCH A: Spontaneous and augmented growth of axons in the primate spinal cord: Effects of local injury and nerve growth factor-secreting cells. J. Comp. Neurol. (2002) 448:88-101.
83. LU P, BLESCH A, TUSZYNSKI MH: Neurotrophism without neurotropism: BDNF promotes survival but not growth of lesioned corticospinal neurons. J. Comp. Neurol. (2001) 436:456-470.
84. LEONE P, JANSON CG, BILANIUK L et al.: Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann. Neurol. (2000) 48:27-38.
85. LI T, DAVIDSON BL: Phenotype correction in retinal pigment epithelium in murine mucopolysaccharidosis VII by adenovirus-mediated gene transfer. Proc. Natl. Acad. Sci. USA (1995) 92:7700-7704. Important study showing benefit of gene therapy in a model of inborn error of metabolism.
86. STEIN CS, GHODSI A, DERKSEN T, DAVIDSON BL: Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis Type VII mice. J. Virol. (1999) 73:3424-3429.
87. DALY TM, VOGLER C, LEVY B, HASKINS ME, SANDS MS: Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc. Natl. Acad. Sci. USA (1999) 96:2296-2300.
88. CONSIGLIO A, QUATTRINI A, MARTINO S et al.: In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat. Med. (2001) 7:310-316.
89. ALLAMAND V, DONAHUE KM, STRAUB V, DAVISSON RL, DAVIDSON BL, CAMPBELL KP: Early adenovirus-mediated gene transfer effectively prevents muscular dystrophy in alpha-sarcoglycan-deficient mice. Gene Ther. (2000) 7:1385-1391.
90. LEARISH R, OHASHI T, ROBBINS PA et al.: Retroviral gene transfer and sustained expression of human arylsulfatase A. Gene Ther. (1996) 3:343-349.
91. LACORAZZA HD, FLAX JD, SNYDER EY, JENDOUBI M: Expression of human bera-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells. Nat. Med. (1996) 2:424-429.
92. HAHN CN, DEL PILAR MARTIN M, ZHOU XY, MANN LW, D'AZZO A. Correction of murine galactosialidosis by bone marrow-derived macrophages oveirexpiressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter. Proc. Natl. Acad. Sci. USA (1998) 95:14880-14885.
93. TAKENAKA T, MURRAY GJ, QIN G et al.: Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc. Natl. Acad. Sci. USA (2000) 97:7515-7520.
94. BETZ AL, YANG GY, DAVIDSON BL: Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J. Cereb. Blood Flow Metab. (1995) 15:547-551.
95. O'CONNOR WM, DAVIDSON BL, KAPLITT MG et al.: Adenovirus vector-mediated gene transfer into human epileptogenic brain slices: prospects for gene therapy in epilepsy. Exp. Neurol. (1997) 148:167-178.
96. SHORT MP, CHOI BC, LEE JK, MAICK A, BREAKEFIELD XO, MARTUZA RL: Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J. Neurosci. Res. (1990) 27:427-439. Description of potential value of gene delivery for nervous system cancer.
97. BARBA D, HARDIN J, RAY J, GAGE FH: Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg. (1993) 79:729-735.
98. CULVER KW, RAM Z, WALLBRIDGE S, ISHII H, OLDFIELD EH, BLAESE RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (1992) 256:1550-1552.
99. NANDA D, DRIESSE MJ, SILLEVIS SMITT PA: Clinical trials of adenoviral-mediated suicide gene therapy of malignant gliomas. Prog. Brain Res. (2001) 132:699-710.
100. ALAVI JB, ECK SL: Gene therapy for high grade gliomas. Expert Opin. Biol. Ther. (2001) 1:239-252.
101. RAM Z, CULVER KW, OSHIRO EM et al.: Therapy of malignant brain tumors by intrantumoral implantation of retroviral vectoir-producing cells. Nat. Med. (1997) 3:1354-1361.
102. SHAND N, WEBER F, MARIANI L et al.: A Phase I-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by gancidovir. GLI328 European-Canadian Study Group. Hum. Gene Ther. (1999) 10:2325-2335.
103. COHEN JL, SARON MF, BOYER O et al.: Preservation of graft-versus-infection effects after suicide gene therapy for prevention of graft-versus-host disease. Hum. Gene Ther. (2000) 11:2473-2481.
104. RAINOV NG: A Phase III dinical evaluation of herpes simplex virus Type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. (2000) 11:2389-2401.
105. MARKERT JM, PARKER JN, GILLESPIE GY, WHITLEY RJ: Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes (2001) 8:17-22.
106. GOSSEN M, BONIN AL, FREUNDLIEB S, BUJARD H: Inducible gene expression systems for higher eukaryotic cells. Curr. Opin. Biotechnol. (1994) 5:516-520. Important report indicating possibility of effective, regulated therapeutic gene expression.
107. BLESCH A, CONNER JM, TUSZYNSKI MH: Modulation of neuronal survival and axonal growth in vivo by tetracydine-regulated neurotrophin expression. Gene Ther. (2001) 8:954-960.
108. FAVRE D, BLOUIN V, PROVOST N et al.: Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J. Virol. (2002) 76:11605-11611. Description of potential pitfalls of regulated gene delivery with tetracycline-sensitive system.
109. SUHR ST, GIL EB, SENUT MC, GAGE FH: High level transactivation by a modified Bombyx ecdysone receptor in mammalian cells without exogenous retinoid X receptor. Proc. Natl. Acad. Sci. USA (1998) 95:7999-8004.
110. NANDA D, VOGELS R, HAVENGA M, AVEZAAT CJ, BOUT A, SMITT PS: Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res. (2001) 61:8743-8750.